| Original language | English |
|---|---|
| Pages (from-to) | 2086-2090 |
| Number of pages | 5 |
| Journal | Journal of Investigative Dermatology |
| Volume | 141 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2021 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Biochemistry
- Molecular Biology
- Dermatology
- Cell Biology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Investigative Dermatology, Vol. 141, No. 8, 08.2021, p. 2086-2090.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - IL-36 and IL-17A Cooperatively Induce a Psoriasis-Like Gene Expression Response in Human Keratinocytes
AU - Miura, Shunsuke
AU - Garcet, Sandra
AU - Salud-Gnilo, Charissa
AU - Gonzalez, Juana
AU - Li, Xuan
AU - Murai-Yamamura, Mika
AU - Yamamura, Kazuhiko
AU - Rambhia, Darshna
AU - Kunjravia, Norma
AU - Guttman-Yassky, Emma
AU - Krueger, James G.
N1 - Funding Information: EGY is an employee of Mount Sinai; has received research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boerhinger Ingelhiem, Celgene, Dermavant, DS Biopharma, Eli Lilly, Galderma, Glenmark/Ichnos Sciences, Innovaderm, Janssen, Kiniksa, Kyowa Kirin, Leo Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron Pharmaceuticals, Sienna Biopharma, UCB, and UNION Therapeutics/Antibiotx; and is a consultant for AbbVie, Aditum Bio, Almirall, Alpine, Amgen, Arena, Asana Biosciences, AstraZeneca, Bluefin Biomedicine, Boehringer Ingelheim, Boston Pharmaceuticals, Botanix, Bristol-Meyers Squibb, Cara Therapeutics, Celgene, Clinical Outcome Solutions, DBV Technologies, Dermavant, Dermira, Douglas Pharmaceutical, DS Biopharma, Eli Lilly, EMD Serono, Evelo Bioscience, Evidera, FIDE, Galderma, GlaxoSmithKline, Haus Bioceuticals, Ichnos Sciences, Incyte, Kyowa Kirin, Larrk Bio, Leo Pharma, Medicxi, Medscape, Neuralstem, Noble Insights, Novan, Novartis, Okava Pharmaceuticals, Pandion Therapeutics, Pfizer, Principia Biopharma, RAPT Therapeutics, Realm, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Sienna Biopharma, Seanegy Dermatology, Seelos Therapeutics, Serpin Pharma, Siolta Therapeutics, Sonoma Biotherapeutics, Sun Pharma, Target RWE, UNION Therapeutics, Vanda Pharmaceuticals, Ventyx Biosciences, and Vimalan. JGK has received research support (grants paid to institution) from AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, EMD Serono, Innovaderm, Kineta, LEO Pharma, Novan, Novartis, Paraxel, Pfizer, Regeneron, and Vitae and personal fees from AbbVie, Acros, Allergan, Aurigne, BiogenIdec, Boehringer Ingelheim, Escalier, Janssen, Lilly, Novartis, Pfizer, Roche, and Valeant. The remaining authors state no conflict of interest. Funding Information: This work was supported in part by a fellowship from the Uehara Memorial Foundation, Japan (award number: 201830050).
PY - 2021/8
Y1 - 2021/8
UR - http://www.scopus.com/inward/record.url?scp=85103972006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103972006&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2021.01.019
DO - 10.1016/j.jid.2021.01.019
M3 - Article
C2 - 33675789
AN - SCOPUS:85103972006
SN - 0022-202X
VL - 141
SP - 2086
EP - 2090
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 8
ER -